RADNOR, Pa., Aug. 22, 2017 -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds Envision Healthcare Corporation (NYSE:EVHC) (“Envision” or the “Company”) shareholders that a class action lawsuit has been filed in the United States District Court for the Middle District of Tennessee against Envision on behalf of purchasers of the Company’s securities between March 2, 2015 and July 21, 2017, inclusive (the “Class Period”).
Important Deadline Reminder: Envision shareholders who purchased securities during the Class Period may, no later than October 3, 2017, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this action please visit www.ktmc.com/new-cases/envision-healthcare-corporation#join.
Envision provides health care services, including surgery, pharmacy, medical imaging, emergency care, and other related services to patients in the United States. EmCare Holdings (“EmCare”) is one of Envision’s primary business units.
The shareholder class action complaint alleges that Envision and certain of its executive officers made a series of false and misleading statements and/or failed to disclose to investors that: (i) EmCare routinely arranged for patients who sought treatment at in-network facilities to be treated by out-of-network physicians; (ii) EmCare accordingly billed these patients at higher rates than if the patients had received treatment from in-network physicians; (iii) the Company’s statements attributing EmCare’s Class Period growth to other factors were therefore false and/or misleading; (iv) Envision’s EmCare revenues were likely to be unsustainable after the foregoing conduct came to light; and (v) as a result of the foregoing, Envision’s public statements were materially false and misleading at all relevant times.
On July 24, 2017, The New York Times reported that hospitals associated EmCare were disproportionately likely to engage in “surprise billing,” in which patients who go to in-network hospitals are treated by out-of-network doctors and subsequently billed at higher rates. Following this news, shares of the Company’s stock declined $2.33 per share, or 3.7%, to close on July 24, 2017 at $60.28. The following day the Company’s stock declined an additional $1.40 per share.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check (Darren J. Check, Esq., D. Seamus Kaskela, Esq. or Adrienne O. Bell, Esq.) at (888) 299–7706 or (610) 667–7706, or via e-mail at [email protected].
Envision shareholders may, no later than October 3, 2017, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.
CONTACT: Kessler Topaz Meltzer & Check, LLP Darren J. Check, Esq. D. Seamus Kaskela, Esq. Adrienne O. Bell, Esq. 280 King of Prussia Road Radnor, PA 19087 (888) 299-7706 (610) 667-7706 [email protected]


Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Robinhood Expands Sports Event Contracts With Player Performance Wagers
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 



